Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pancreatic Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Urinary Bladder Neoplasms 33Neoplasm Metastasis 20Lung Neoplasms 20Ovarian Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Neoplasms 14Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Fallopian Tube Neoplasms 10Recurrence 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Melanoma 4Gastrointestinal Neoplasms 4

Interventions

tocilizumab 2talquetamab 1siltuximab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Gemcitabine × 90 days × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡